top of page

Nivolumab 40mg Injection

$600.00Price
40 MG
1 VIAL
2 VIAL
3 VIAL
4 VIAL

Injection is used in the treatment of non-small cell lung cancer, kidney cancer, head and neck cancer, melanoma, Hodgkin's disease, and liver cancer.

About This Medicine

Short Description


Nivolumab 40 mg Injection is an immunotherapy medicine used to treat certain types of cancer. It belongs to a class of medicines called PD-1 inhibitors, which help the immune system recognise and attack cancer cells. It may be used alone or in combination with other cancer treatments, depending on the cancer type and treatment plan.


What Is Nivolumab 40 mg Injection?


Nivolumab is a monoclonal antibody and immune checkpoint inhibitor used in cancer treatment. It works by targeting programmed cell death protein 1 (PD-1), a receptor found on certain immune cells.


Some cancer cells use the PD-1 pathway to reduce the immune system's ability to attack them. By blocking this pathway, nivolumab helps restore the immune response against cancer cells.


Uses


Nivolumab 40 mg Injection may be prescribed to:


  • Treat advanced or metastatic melanoma (skin cancer).

  • Treat certain types of non-small cell lung cancer.

  • Treat advanced renal cell carcinoma (kidney cancer).

  • Treat classical Hodgkin lymphoma in eligible patients.

  • Treat certain cancers of the head and neck.

  • Treat selected cases of bladder cancer (urothelial carcinoma).

  • Treat certain cancers of the stomach, oesophagus, and gastroesophageal junction.

  • Treat selected cases of liver cancer (hepatocellular carcinoma).


Nivolumab may be used alone or alongside other cancer treatments, depending on the diagnosis, cancer stage, and applicable treatment guidelines. Approved indications vary between countries. The treatment regimen must be determined by an oncologist.


How Does Nivolumab Work?


Nivolumab works by blocking the programmed cell death protein 1 (PD-1) receptor on immune cells called T cells.


Some cancer cells use the PD-1 pathway to suppress immune activity and avoid being recognised by the body's defence system. Nivolumab blocks this interaction, helping T cells recognise and attack cancer cells.


The response to treatment varies depending on the cancer type, individual circumstances, and whether nivolumab is used alone or with other treatments.


How to Take Nivolumab 40 mg Injection


Nivolumab 40 mg Injection must be administered by a qualified healthcare professional under the supervision of an oncologist.


  • It is given as an intravenous (IV) infusion into a vein.

  • The medicine is supplied as a concentrate that must be diluted and prepared before administration.

  • The infusion is generally administered over approximately 30 minutes, depending on the prescribed regimen and product instructions.

  • The frequency of treatment depends on the cancer type, treatment combination, and individual treatment plan.

  • Your healthcare team may perform regular blood tests and clinical assessments during treatment.

  • Do not miss scheduled appointments or change the treatment schedule without consulting your oncologist.


The dose and duration of treatment are determined by the treating specialist.


Important Safety Information


Before starting Nivolumab 40 mg Injection, inform your oncologist about your medical history, existing health conditions, and all medicines, supplements, and herbal products you use.


Use this medicine with particular caution if you have:


  • An autoimmune disease, such as rheumatoid arthritis or lupus.

  • A history of organ or stem cell transplantation.

  • Previous lung inflammation or breathing disorders.

  • Liver or kidney problems.

  • Thyroid or other hormonal disorders.

  • A history of severe reactions to immunotherapy.


Important medicine interactions:


  • Immunosuppressants, including corticosteroids, may affect the immune response to treatment.

  • Other immune checkpoint inhibitors or immunotherapy medicines may increase the risk of immune-related adverse reactions.

  • Other anticancer medicines used in combination with nivolumab may require additional monitoring.


Nivolumab can cause the immune system to attack healthy organs and tissues, sometimes resulting in serious complications. Your healthcare team may monitor liver function, kidney function, thyroid function, and other relevant health indicators during treatment.


Check all possible medicine interactions and existing health conditions with your oncologist before starting treatment.


Pregnancy & Breastfeeding


Nivolumab is generally not recommended during pregnancy because it may affect the developing baby's immune system. Its use during pregnancy should only be considered by a specialist when the potential benefits justify the possible risks.


Women who can become pregnant are generally advised to use effective contraception during treatment and for at least 5 months after the last dose.


It is not known whether nivolumab passes into human breast milk. Breastfeeding is generally not recommended during treatment, and the decision about stopping breastfeeding or treatment should be discussed with a healthcare professional.


Inform your oncologist if you are pregnant, planning pregnancy, or breastfeeding before receiving this medicine.


Side Effects


Like all medicines, Nivolumab 40 mg Injection can cause side effects, although not everyone experiences them.


Common side effects may include:


  • Tiredness or fatigue.

  • Skin rash or itching.

  • Diarrhoea.

  • Nausea.

  • Musculoskeletal pain.

  • Cough.

  • Reduced appetite.

  • Joint pain.

  • Constipation.


Important warning signs: Nivolumab can cause serious immune-related reactions affecting the lungs, liver, intestines, kidneys, skin, and hormone-producing glands. Seek prompt medical attention if you experience breathing difficulties, persistent diarrhoea or blood in stools, yellowing of the skin or eyes, severe abdominal pain, unusual headaches, vision changes, or significant muscle weakness.


Some immune-related reactions can develop during treatment or even after treatment has ended. Report new or worsening symptoms to your healthcare team promptly.

This is not a complete list of side effects or warnings. Please refer to the product packaging and patient information leaflet supplied with your medicine for complete information and speak with your doctor or pharmacist if you have concerns.


Storage


Store Nivolumab 40 mg Injection according to the instructions shown on the original product packaging.


  • Store under refrigeration at 2°C to 8°C.

  • Keep the vial in its original packaging to protect it from light.

  • Do not freeze the medicine.

  • Do not shake the vial.

  • Keep out of reach of children.

  • Do not use the medicine after its expiry date.


The preparation and storage of diluted solutions must follow the manufacturer's instructions and be handled by qualified healthcare professionals.


Frequently Asked Questions


1. What is Nivolumab 40 mg Injection used for?

Nivolumab is an immunotherapy medicine used to treat certain cancers, including melanoma, lung cancer, kidney cancer, and other selected cancers. Its use depends on the cancer type, stage, and individual treatment requirements.


2. How does Nivolumab work against cancer?

Nivolumab blocks the PD-1 receptor on immune cells, helping the immune system recognise and attack cancer cells. It works by supporting the body's immune response rather than directly targeting cancer cells like conventional chemotherapy.


3. How is Nivolumab 40 mg Injection administered?

It is administered through an intravenous infusion by a qualified healthcare professional. The medicine must be prepared and diluted according to the manufacturer's instructions before administration.


4. How long does Nivolumab take to work?

The time required to respond to nivolumab varies between individuals and cancer types. Some patients may require several treatment cycles before their response can be assessed through clinical evaluations and imaging tests.


5. Can Nivolumab be used with chemotherapy?

Yes. Nivolumab may be prescribed alongside certain chemotherapy medicines or other immunotherapy treatments for specific cancers. The combination depends on the approved treatment indication and the oncologist's assessment.


6. What happens if I miss a scheduled Nivolumab infusion?

Contact your oncology team as soon as possible if you miss a scheduled infusion. Your healthcare professional will advise when the next treatment should be given based on your treatment plan.


7. Should Nivolumab treatment be stopped if I feel better?

Do not stop or delay treatment without consulting your oncologist. Treatment duration depends on the cancer type, response to therapy, side effects, and the prescribed treatment protocol.


bottom of page